Pharma BD Deal Intelligence
Warner-Lambert's $2.1 billion all-stock buy of Agouron secured Viracept and a structure-based drug discovery platform, but Agouron never operated independently for long—Pfizer absorbed the whole portfolio the following year through its 2000 takeover of Warner-Lambert itself.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
In January 1999 Warner-Lambert agreed to acquire Agouron Pharmaceuticals for approximately $2.1 billion in stock, gaining the HIV protease inhibitor Viracept (nelfinavir) and Agouron's structure-based drug discovery platform. Agouron subsequently became part of Pfizer through Pfizer's 2000 acquisition of Warner-Lambert.
40K US cases/yr · $4.5B US HIV/AIDS Rx Market (1999)
Agouron Pharmaceuticals was acquired by Warner-Lambert for $2.1B in 1999, bringing Viracept (nelfinavir), the nation's best-selling HIV protease inhibitor at the time. Viracept's launch was the largest biotech product launch in history, achieving $335M in its first full year of sales.
Viracept was a key component of highly active antiretroviral therapy (HAART), the triple-drug cocktail that transformed HIV from a death sentence to a manageable chronic disease. Pfizer inherited Agouron through its 2000 Warner-Lambert acquisition, continuing HIV franchise development.
Pfizer completed $2.1B acquisition of Agouron Pharmaceuticals, gaining Viracept (nelfinavir) HIV protease inhibitor and drug design capabilities.
Viracept generated significant HIV revenue in early HAART era before being superseded by next-gen protease inhibitors with better profiles.
Viracept commercially successful initially but displaced by superior HIV treatments. Lasting value was Agouron's structure-based drug design integrated into Pfizer R&D.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Agouron Pharmaceuticals (this deal) | 1999 | $2.1B | 74 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 1999 deals · Pfizer Inc. deals · Infectious Disease deals